Expansions at sites in Le Mans and Mourenx, France have solidified the CDMO’s position in targeting the hot antibody-drug conjugate and peptide purification markets.
The collaboration will support the full product lifecycle, from early research and IND submissions to clinical development and commercialization, all from College Station, Texas.
